LU90656I2 - Hydrochlorure de bupropion - Google Patents

Hydrochlorure de bupropion

Info

Publication number
LU90656I2
LU90656I2 LU90656C LU90656C LU90656I2 LU 90656 I2 LU90656 I2 LU 90656I2 LU 90656 C LU90656 C LU 90656C LU 90656 C LU90656 C LU 90656C LU 90656 I2 LU90656 I2 LU 90656I2
Authority
LU
Luxembourg
Prior art keywords
hydrochloride
bupropion hydrochloride
tablet
bupropion
release
Prior art date
Application number
LU90656C
Other languages
English (en)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10720358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90656(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of LU90656I2 publication Critical patent/LU90656I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • General Preparation And Processing Of Foods (AREA)
LU90656C 1992-08-14 2000-10-18 Hydrochlorure de bupropion LU90656I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929217295A GB9217295D0 (en) 1992-08-14 1992-08-14 Controlled released tablets
PCT/GB1993/001722 WO1994004138A1 (fr) 1992-08-14 1993-08-13 Comprimes a liberation prolongee contenant du bupropione

Publications (1)

Publication Number Publication Date
LU90656I2 true LU90656I2 (fr) 2001-01-15

Family

ID=10720358

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90656C LU90656I2 (fr) 1992-08-14 2000-10-18 Hydrochlorure de bupropion

Country Status (21)

Country Link
US (1) US5427798A (fr)
EP (1) EP0656775B1 (fr)
JP (1) JPH08500110A (fr)
KR (1) KR100294154B1 (fr)
AT (1) ATE161422T1 (fr)
AU (1) AU677595B2 (fr)
CA (1) CA2142320C (fr)
CY (1) CY2143B1 (fr)
DE (1) DE69316015T2 (fr)
ES (1) ES2111168T3 (fr)
GB (1) GB9217295D0 (fr)
GR (1) GR3025794T3 (fr)
HK (1) HK1004323A1 (fr)
IL (1) IL106693A (fr)
LU (1) LU90656I2 (fr)
MX (1) MX9304967A (fr)
NZ (1) NZ254947A (fr)
SG (1) SG43911A1 (fr)
TW (1) TW260607B (fr)
WO (1) WO1994004138A1 (fr)
ZA (1) ZA935942B (fr)

Families Citing this family (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5616344A (en) * 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
CN1623533A (zh) * 1997-09-25 2005-06-08 拜尔公司 控释活性化合物的药物制剂
US6221917B1 (en) 1997-12-30 2001-04-24 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5968553A (en) * 1997-12-30 1999-10-19 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
WO1999038504A1 (fr) 1998-01-29 1999-08-05 Sepracor Inc. Utilisations pharmaceutiques de (-)-bupropion optiquement pur
CA2318921A1 (fr) 1998-01-29 1999-08-05 John R. Mccullough Usages pharmacologiques de (+)-bupropion optiquement pur
WO1999038499A2 (fr) * 1998-01-29 1999-08-05 Sepracor Inc. Procedes et compositions de (-)-bupropion optiquement pur destines a faciliter la desaccoutumance au tabac et au traitement de douleurs et d'autres troubles
JP2002501890A (ja) * 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（＋）−ビュープロピオンの薬学的使用
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
US6153223A (en) * 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6855820B2 (en) * 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US6589553B2 (en) * 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
USD430285S (en) * 1999-04-16 2000-08-29 Merck & Co., Inc. Tablet
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
JP2004510687A (ja) * 1999-11-02 2004-04-08 ディポメド，インコーポレイティド 胃への薬剤投与の強化のための供給モードの薬理学的誘導
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
WO2002062299A2 (fr) * 2001-02-08 2002-08-15 Andrx Pharmaceuticals, Inc. Forme posologique orale a liberation regulee amelioree
ITMI20011457A1 (it) * 2001-07-09 2003-01-09 Valpharma Sa Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
WO2003097046A1 (fr) * 2002-05-17 2003-11-27 Duke University Procede de traitement de l'obesite
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP1558211A2 (fr) * 2002-10-30 2005-08-03 Pharmacia Corporation Comprimes oraux a liberation etendue et procedes de fabrication et d'utilisation associes
US20040096497A1 (en) * 2002-11-19 2004-05-20 Ponder Garratt W. Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
DE602004012403T2 (de) * 2003-04-29 2009-03-19 Orexigen Therapeutics, Inc., La Jolla Zusammensetzungen zur beeinflussung des gewichtsverlusts
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
SI1575565T1 (sl) * 2003-08-08 2010-04-30 Biovail Lab Int Srl Tableta bupropion hidroklorida z modificiranim sprošŽŤanjem
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
BRPI0506829A (pt) 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
USD515202S1 (en) 2004-07-19 2006-02-14 Merck & Co., Inc Tablet
US8586085B2 (en) 2004-11-08 2013-11-19 Biokey, Inc. Methods and formulations for making pharmaceutical compositions containing bupropion
US20060099262A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
GB0425445D0 (en) * 2004-11-18 2004-12-22 Smithkline Beecham Corp Novel compositions
KR100670798B1 (ko) 2004-12-17 2007-01-17 한국전자통신연구원 데이터베이스 캐시 시스템
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
US20070112075A1 (en) * 2005-10-14 2007-05-17 Forest Laboratories, Inc. Stable pharmaceutical formulations containing escitalopram and bupropion
WO2007053796A2 (fr) * 2005-10-14 2007-05-10 Forest Laboratories, Inc. Procedes de traitement de troubles du systeme nerveux central avec une combinaison de faible dose d'escitaloprame et de bupropion
PL2135603T3 (pl) 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
AR057946A1 (es) * 2005-11-28 2007-12-26 Orexigen Therapeutics Inc Formulacion de zonisamida de liberacion sostenidda
EP1999303A4 (fr) * 2006-02-27 2010-09-08 Univ Leland Stanford Junior Procédés permettant d'identifier les inhibiteurs de réponse aux protéines dépliées
US20090181098A1 (en) 2006-03-07 2009-07-16 Osteoscreen Ip, Llc Hmg-Co-a Reductase Inhibitor Enhancement of Bone and Cartilage
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007305138A1 (en) 2006-06-13 2008-04-10 The Board Of Trustees Of The Leland Stanford Junior University Epoxide inhibitors of cysteine proteases
US7674479B2 (en) * 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
US20100008987A1 (en) * 2006-08-21 2010-01-14 Pasula Basavaiah Chowdary Modified Release Pharmaceutical Composition of Bupropion Hydrochloride
TW200829235A (en) 2006-11-09 2008-07-16 Orexigen Therapeutics Inc Methods for administering weight loss medications
EP2089005B1 (fr) 2006-11-09 2010-03-17 Orexigen Therapeutics, Inc. Formulations pharmaceutiques en couches comprenant une couche intermédiaire à dissolution rapide
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
EP2142183A2 (fr) 2007-04-09 2010-01-13 Sepracor Inc. Procédés et compositions destinées au traitement de troubles respiratoires liés au sommeil
JP2010530422A (ja) * 2007-06-18 2010-09-09 ザ ジェネラル ホスピタル コーポレイション うつ病のための組合せ治療
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
US9339500B2 (en) 2008-03-04 2016-05-17 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
KR101690094B1 (ko) 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
TW201039815A (en) 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
ES2428938T3 (es) 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
CA2765971C (fr) 2009-07-22 2017-08-22 Gruenenthal Gmbh Forme galenique extrudee a chaud a liberation controlee
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
WO2011095314A2 (fr) 2010-02-03 2011-08-11 Grünenthal GmbH Préparation d'une composition pharmaceutique pulvérulente au moyen d'une extrudeuse
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
JP2013539786A (ja) 2010-10-11 2013-10-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 置換ベンズアミドおよびその使用法
HUE027317T2 (en) 2010-10-26 2016-10-28 Mars Inc Boronates as arginase inhibitors
PL2736495T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
HRP20171458T1 (hr) 2011-07-29 2017-11-17 Grünenthal GmbH Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
ES2761866T3 (es) 2011-11-21 2020-05-21 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
WO2013127831A1 (fr) 2012-02-28 2013-09-06 Grünenthal GmbH Forme pharmaceutique inviolable comprenant un composé pharmacologiquement actif et un polymère anionique
CA2873701A1 (fr) 2012-04-12 2013-10-17 Auckland Uniservices Limited Benzamides substituees et leurs utilisations
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2875056C (fr) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methodes de traitement de la surcharge ponderale et de l'obesite
ES2899461T3 (es) 2012-11-16 2022-03-11 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
WO2014145257A2 (fr) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Composés de sonde basée sur l'activité, compositions et méthodes d'utilisation
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
JP2017518980A (ja) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールを含む、改変防止即時放出カプセル製剤
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
MX374924B (es) 2014-06-13 2025-03-06 Calithera Biosciences Inc Terapia de combinacion con inhibidores de glutaminasa.
BR112017002403A2 (pt) 2014-08-07 2017-12-05 Calithera Biosciences Inc formas de cristais de inibidores de glutaminase
UY36272A (es) 2014-08-13 2016-02-29 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores de los receptores de orexinas
EP3212195A4 (fr) 2014-10-31 2018-06-06 The Regents of The University of California Compositions et méthodes de traitement d'un dysfonctionnement cognitif associé au vih
CA3220902A1 (fr) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited Composes 1,2,4-oxadiazoles et thiadiazoles utilises comme immunomodulateurs
KR20170139158A (ko) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태
MX385315B (es) 2015-06-23 2025-03-14 Calithera Biosciences Inc Composiciones y metodos para inhibir actividad de arginasa.
US10016471B2 (en) 2015-06-29 2018-07-10 Phloronol, Inc. Solid pharmaceutical compositions of brown algae
WO2017042325A1 (fr) 2015-09-10 2017-03-16 Grünenthal GmbH Protection contre un surdosage par voie orale à l'aide de formulations à libération immédiate dissuasives d'abus
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CN108601767A (zh) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
PT3368541T (pt) 2015-10-30 2020-07-06 Calithera Biosciences Inc Composições e métodos para inibição da atividade da arginase
WO2017087517A1 (fr) 2015-11-16 2017-05-26 Demeter Therapeutics, Llc Promédicaments d'acides nucléiques
TWI710557B (zh) 2016-02-12 2020-11-21 美商伊歐拉斯治療學公司 作為食慾素受體調節劑之經鹵素取代之六氫吡啶
US20210177770A1 (en) 2016-04-14 2021-06-17 Spinnaker Biosciences, Inc. Porous silicon materials comprising a metal silicate for delivery of therapeutic agents
CN110200978B (zh) 2016-04-22 2023-10-31 维京治疗股份有限公司 甲状腺β-激动剂的应用
WO2017210565A1 (fr) 2016-06-03 2017-12-07 Prisident And Fellows Of Harvard College Composés antifongiques
US11077151B2 (en) 2016-08-25 2021-08-03 California Institute Of Technology Ascaroside treatment of autoimmune and inflammatory diseases
WO2018039612A1 (fr) 2016-08-26 2018-03-01 The Regents Of The University Of California Compositions et méthodes favorisant la croissance des cheveux au moyen d'inhibiteurs de mpc1
WO2018049027A1 (fr) 2016-09-07 2018-03-15 Trustees Of Tufts College Polythérapies mettant en oeuvre des inhibiteurs d'immuno-dash et des antagonistes de pge2
US10472364B2 (en) 2016-09-09 2019-11-12 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
US10980767B2 (en) 2016-09-09 2021-04-20 The Regents Of The University Of California Estrogen receptor ligands, compositions and methods related thereto
JP7203018B2 (ja) 2016-09-26 2023-01-12 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド クロモボックスタンパク質阻害剤およびその使用
SI3519050T1 (sl) 2016-09-28 2023-10-30 Medicon Pharmaceuticals, Inc. Sestavki za zdravljenje očesnih obolenj
MX2019003623A (es) 2016-09-28 2019-09-23 Medicon Pharmaceuticals Inc Composiciones y metodos para el tratamiento de afecciones oftalmicas.
CA3042878A1 (fr) 2016-11-08 2018-05-17 Calithera Biosciences, Inc. Polytherapies faisant appel a un inhibiteur d'arginase
AU2017364077A1 (en) 2016-11-22 2019-06-20 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
ES2970715T3 (es) 2016-12-22 2024-05-30 Prec Pharmaceuticals Inc Composiciones y métodos para inhibir la actividad de la arginasa
CN110023740B (zh) 2016-12-23 2023-04-14 里兰斯坦福初级大学理事会 基于活性的探针化合物、组合物及其使用方法
BR112019014759A2 (pt) 2017-01-18 2020-03-03 Vanderbilt University Compostos heterocíclicos fundidos como inibidores seletivos de bmp
AU2018223982B2 (en) 2017-02-24 2022-02-03 Merck Patent Gmbh 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors
IL305150B2 (en) 2017-03-31 2025-03-01 Aurigene Oncology Ltd Compounds and preparations for the treatment of hematological disorders
US10994025B2 (en) 2017-05-12 2021-05-04 Massachusetts Institute Of Technology Argonaute protein-double stranded RNA complexes and uses related thereto
WO2018223032A1 (fr) 2017-06-02 2018-12-06 Stealth Biotherapeutics Corp. Formes cristallines de sel de sbt-20
CN116120314A (zh) 2017-06-30 2023-05-16 加利福尼亚大学董事会 用于调节毛发生长的组合物和方法
US10526334B2 (en) 2017-07-19 2020-01-07 California Institute Of Technology Methods for preparing bis-tetrahydroisoquinoline-containing compounds
WO2019023392A1 (fr) 2017-07-25 2019-01-31 Elektrofi, Inc. Formation de particules comprenant des agents
CN118459413A (zh) 2017-09-26 2024-08-09 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
AU2018346331B2 (en) 2017-10-04 2023-08-24 Dana-Farber Cancer Institute, Inc. Small molecule inhibition of transcription factor SALL4 and uses thereof
BR112020006669A2 (pt) 2017-10-11 2020-09-24 Aurigene Discovery Technologies Limited formas cristalinas de 1,2,4-oxadiazol 3-substituído
SI3704108T1 (sl) 2017-10-31 2024-07-31 Curis, Inc. Inhibitor irak4 v kombinaciji z inhibitorjem bcl-2 za uporabo pri zdravljenju raka
MY206121A (en) 2017-11-03 2024-11-29 Aurigene Discovery Tech Ltd Dual inhibitors of tim-3 and pd-1 pathways
KR20200084333A (ko) 2017-11-06 2020-07-10 오리진 디스커버리 테크놀로지스 리미티드 면역조절을 위한 병행 요법
KR20200104335A (ko) 2017-12-22 2020-09-03 메디뮨 리미티드 Keap1의 BTB 도메인의 소분자 조절제
WO2019152536A1 (fr) 2018-01-30 2019-08-08 The Regents Of The University Of California Inhibiteurs de la voie wnt/bêta-caténine
EP3765460A1 (fr) 2018-03-14 2021-01-20 Vanderbilt University Inhibition de la signalisation bmp, composés, compositions et leurs utilisations
KR20200131247A (ko) 2018-03-14 2020-11-23 오리진 디스커버리 테크놀로지스 리미티드 1,2,4-옥사다이아졸 화합물을 사용하여 tigit 및 pd-1 신호전달 경로를 조절하는 방법
JP2021521280A (ja) 2018-04-12 2021-08-26 マトルクス セラピューティクス コーポレーション 弾性線維分解を治療するための組成物及び方法
US11155638B2 (en) 2018-05-08 2021-10-26 Rhode Island Hospital Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
JP7402225B2 (ja) 2018-05-11 2023-12-20 ロード アイランド ホスピタル ヌクレオシド系逆転写酵素阻害剤を用いて関節障害を処置するための組成物および方法
WO2019226969A1 (fr) 2018-05-24 2019-11-28 Elektrofi, Inc. Particules comprenant un agent thérapeutique ou diagnostique et suspensions et leurs procédés d'utilisation
US20210122771A1 (en) 2018-06-29 2021-04-29 The Regents Of The University Of California New molecular tweezers against neurological disorders and viral infections
EP3830082B1 (fr) 2018-07-27 2025-02-26 California Institute of Technology Inhibiteurs de cdk et leurs utilisations
US20220218652A1 (en) 2018-09-05 2022-07-14 The General Hospital Corporation Methods of treating cytokine release syndrome
WO2020056109A1 (fr) 2018-09-12 2020-03-19 The Board Of Regents Of The University Of Oklahoma Polythérapies anticancéreuses
EP3867223B1 (fr) 2018-10-17 2025-12-10 The Regents of the University of California Promédicaments d'alpha-cétoglutarate, d'alpha-cétobutyrate, d'alpha-cétoisovalérate, et d'alpha-cétoisohexanoate, et leurs utilisations
CA3117695A1 (fr) 2018-10-26 2020-04-30 Keros Therapeutics, Inc. Formes cristallines d'un inhibiteur d'alk2
IL282530B2 (en) 2018-10-31 2025-07-01 Intocell Inc History of compressed heterocyclic benzodiazepines and their uses
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
EP4470609A3 (fr) 2019-01-18 2025-03-12 Astrazeneca AB Inhibiteurs de pcsk9 et leurs procédés d'utilisation
PH12021551734A1 (en) 2019-01-25 2022-07-25 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
WO2020160323A2 (fr) 2019-01-31 2020-08-06 Elektrofi, Inc. Formation et morphologie de particules
WO2020183021A1 (fr) 2019-03-14 2020-09-17 Astrazeneca Ab Lanabecestat pour perte de poids
EP3978076A4 (fr) 2019-06-03 2023-02-22 Irimajiri Therapeutics Inc. Composés d'amide cyclique pour le traitement de la rage et méthode associée
CN114514035A (zh) 2019-09-13 2022-05-17 伊勒卓菲公司 递送用于治疗疾病的治疗性生物制剂的组合物和方法
CN114981243A (zh) 2019-11-12 2022-08-30 健赞公司 用于治疗由cftr活性缺陷介导的疾病和病状的6元杂芳基氨基磺酰胺
WO2021113806A1 (fr) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides et leurs procédés d'utilisation
WO2021113809A1 (fr) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides et leurs procédés d'utilisation
EP4079309A4 (fr) 2019-12-16 2024-01-10 Ulsan National Institute of Science and Technology (UNIST) Composé destiné à inhiber le facteur d'angiogenèse et son utilisation
EP4087847A4 (fr) 2020-01-10 2024-02-28 The Regents of the University of California Compositions et méthodes de traitement de maladies neurodégénératives
WO2021158959A2 (fr) 2020-02-07 2021-08-12 Elektrofi, Inc. Particules peptidiques et procédés de formation
US20230065628A1 (en) 2020-02-19 2023-03-02 Elektrofi, Inc. Droplet Formation and Particle Morphology
IL296196A (en) * 2020-03-05 2022-11-01 Abbvie Inc Methods of administering elagolix
EP4132914A4 (fr) 2020-04-06 2024-04-03 The Regents of the University of California Composés et procédés pour induire l'expression d'ucp1
AU2021257476A1 (en) 2020-04-17 2022-11-03 Elektrofi, Inc. Methods of forming particles by continuous droplet formation and dehydration
BR112022022530A2 (pt) 2020-05-05 2023-02-23 Nuvalent Inc Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alk
EP4146626A4 (fr) 2020-05-05 2024-05-29 Nuvalent, Inc. Agents chimiothérapeutiques à base d'éthers macrocycliques hétéroaromatiques
WO2021263072A1 (fr) 2020-06-25 2021-12-30 Dana-Farber Cancer Institute, Inc. Méthodes de traitement d'une maladie
CN111830151B (zh) * 2020-07-01 2021-05-04 迪沙药业集团有限公司 盐酸安非他酮组合物质量控制用系统适用性对照品
WO2022035804A1 (fr) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. 3-amino-4-méthylbenzènesulfonamides substitués en tant qu'inhibiteurs à petites molécules de la protéase 28 spécifique à l'ubiquitine
EP4192838A1 (fr) 2020-08-10 2023-06-14 Dana-Farber Cancer Institute, Inc. Inhibiteurs à petites molécules pyrimidine-thiéno-pyridine tricycliques fusionnées de la protéase 28 spécifique de l'ubiquitine
CA3191164A1 (fr) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. 1,2,4-oxadiazoles substitues utilises en tant qu'inhibiteurs de petites molecules de la protease 28 specifique de l'ubiquitine
EP4232161A1 (fr) 2020-10-23 2023-08-30 Dana-Farber Cancer Institute, Inc. Inhibiteurs covalents de créatine kinase (ck) et leurs utilisations dans le traitement et la prévention du cancer
WO2022133237A2 (fr) 2020-12-18 2022-06-23 Cornell University Méthodes de traitement de troubles neurodégénératifs et de cancers liés à stat3 au moyen de suppresseurs de fuite d'électrons
IL303813A (en) 2020-12-21 2023-08-01 Univ Cornell Peptide-linked drug delivery system
US20240132480A1 (en) 2021-01-08 2024-04-25 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
BR112023021111A2 (pt) 2021-04-13 2023-12-19 Nuvalent Inc Composto, composição farmacêutica, método de tratamento de câncer, método para inibir seletivamente her2, método de regulação de um nível de her2, método para aumentar um nível de her2, método de diminuição da fosforilação de her2
WO2023034992A1 (fr) 2021-09-03 2023-03-09 Genzyme Corporation Composés indoles et procédés d'utilisation
WO2023034946A1 (fr) 2021-09-03 2023-03-09 Genzyme Corporation Composés indoles et leurs utilisations dans le traitement de la fibrose kystique
IL311444A (en) 2021-10-01 2024-05-01 Nuvalent Inc Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
IL311387A (en) 2021-10-01 2024-05-01 Nuvalent Inc Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
WO2023187422A1 (fr) 2022-03-31 2023-10-05 Revolo Biotherapeutics Limited Compositions et leur utilisation dans des procédés pour traiter une inflammation intestinale
TW202400608A (zh) 2022-04-07 2024-01-01 美商努法倫特公司 雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
CA3245914A1 (fr) 2022-04-07 2023-10-12 Nuvalent, Inc Méthodes de traitement d'une tumeur solide à l'aide de (19r)-5-chloro-3-éthyl-16-fluoro-10,19-diméthyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6. 08,12.013,18]pentacosa-1(24), 2(6),4,8,11,13,15,17,21(25),22-décaén-22-amine
WO2023212721A1 (fr) 2022-04-29 2023-11-02 Elektrofi, Inc. Suspensions injectables
CN119562822A (zh) 2022-05-16 2025-03-04 雷沃洛生物医疗有限公司 用于预防或治疗食物过敏的方法和组合物
WO2023250157A1 (fr) 2022-06-24 2023-12-28 Cornell University Inhibiteurs de mycobacterium tuberculosis lipoamide déshydrogénase
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
CN118785900A (zh) * 2022-06-30 2024-10-15 艾克萨姆治疗公司 包含安非他酮和半胱氨酸的药物组合物
JP2025525415A (ja) 2022-07-13 2025-08-05 アストラゼネカ・アクチエボラーグ Ｐｃｓｋ９阻害剤およびその使用方法
AU2023317392A1 (en) 2022-08-04 2025-02-20 Dks Co. Ltd. Cyclic peptide derivative, method for producing same, and composition
WO2024036097A1 (fr) 2022-08-12 2024-02-15 Nuvalent, Inc. Composés d'éther macrocycliques hétéroaromatiques et isotopologues de ceux-ci
WO2024036098A1 (fr) 2022-08-12 2024-02-15 Nuvalent, Inc. Composés d'éther macrocycliques hétéroaromatiques
WO2024073334A1 (fr) 2022-09-26 2024-04-04 Rose Research Center, Llc Combinaison destinée à être utilisée dans un procédé de prévention de gain de poids
EP4578856A1 (fr) 2022-09-30 2025-07-02 Ubience Inc. Composé hétérocyclique
IL319591A (en) 2022-09-30 2025-05-01 Dks Co Ltd Cyclic peptide derivative composition for treating or preventing eye diseases
IL319638A (en) 2022-10-19 2025-05-01 Nuvalent Inc Chemotherapeutic agents of heteroaromatic macrocyclic esters
CN120187444A (zh) 2022-11-04 2025-06-20 第一工业制药株式会社 用于处置或预防神经病理性疼痛和/或炎性疼痛的环状肽衍生物组合物
TW202525320A (zh) 2022-11-04 2025-07-01 日商第一工業製藥股份有限公司 用於處置或預防中樞神經系損傷疾病的環狀胜肽衍生物組成物
WO2024218571A1 (fr) 2023-04-18 2024-10-24 Revolo Biotherapeutics Limited Méthodes et compositions pour prévenir ou traiter l'oesophagite à éosinophiles
WO2024233456A1 (fr) 2023-05-05 2024-11-14 The Board Of Regents Of The University Of Oklahoma Variants d'adrénomédulline (am) et d'adrénomédulline 2/intermédine (am2/imd) et procédés d'utilisation
WO2025037259A1 (fr) 2023-08-15 2025-02-20 Revolo Biotherapeutics Limited Méthodes et compositions pour la prévention ou le traitement de l'asthme sévère
WO2025042868A1 (fr) 2023-08-23 2025-02-27 The Board Of Regents Of The University Of Oklahoma Combinaisons d'hétéroarotinoïdes et d'inhibiteurs glycolytiques destinées à être utilisées en tant que traitements du cancer
WO2025064475A2 (fr) 2023-09-18 2025-03-27 Flagship Pioneering Innovations Vii, Llc Compositions lipidoïdes ionisables et leurs utilisations thérapeutiques
WO2025072120A1 (fr) 2023-09-25 2025-04-03 Nuvalent, Inc. Composés d'éther macrocycliques hétéroaromatiques
WO2025072117A1 (fr) 2023-09-25 2025-04-03 Nuvalent, Inc. Composés d'éther macrocycliques hétéroaromatiques et isotopologues de ceux-ci
WO2025085360A1 (fr) 2023-10-16 2025-04-24 The Board Of Regents Of The University Of Oklahoma Hétéroarotinoïdes et/ou inhibiteurs de cdk4/6 pour le traitement des verrues, des dysplasies induites par le papillomavirus humain (vph), et du cancer chez des individus infectés par le vph
WO2025088586A1 (fr) 2023-10-27 2025-05-01 Brown University Compositions, systèmes et méthodes de traitement du cancer à l'aide de champs de traitement de tumeur avec des inhibiteurs de mif, mica et/ou micb
TW202535835A (zh) 2023-11-14 2025-09-16 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 可電離類脂質組成物及其治療用途
WO2025212478A1 (fr) 2024-04-01 2025-10-09 Nuvalent, Inc. Méthodes de traitement d'une tumeur solide à l'aide de composés éther macrocycliques hétéroaromatiques
WO2025235872A1 (fr) 2024-05-10 2025-11-13 Schrödinger, Inc. Hétérocycles en tant qu'inhibiteurs d'egfr
WO2025235874A1 (fr) 2024-05-10 2025-11-13 Schrödinger, Inc. Hétérocycles utiliséés en tant qu'inhibiteurs d'egfr
WO2025259911A1 (fr) 2024-06-12 2025-12-18 Elektrofi, Inc. Détection de contaminants particulaires dans des particules et des compositions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759838A (fr) * 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
US3885046A (en) * 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
CA948388A (en) * 1970-02-27 1974-06-04 Paul B. Hansen Pattern bonded continuous filament web
US4347257A (en) * 1979-10-09 1982-08-31 Burroughs Wellcome Co. Prolactin suppression in mammals
IT1142259B (it) * 1980-01-21 1986-10-08 Wellcome Found Combinazioni di composti chetonici ed eterociclici utili come tranquillanti e relativo procedimento di produzione
US4347177A (en) * 1980-04-14 1982-08-31 Burroughs Wellcome Co. Compounds and methods of making them
US4347176A (en) * 1980-04-14 1982-08-31 Burroughs Wellcome Co. Compounds and methods of making same
US4355179A (en) * 1980-04-14 1982-10-19 Burroughs Wellcome Co. Radioactive nuclide labeled propiophenone compounds
US4347382A (en) * 1980-04-15 1982-08-31 Burroughs Wellcome Co. 3H Labeled compounds
US4347178A (en) * 1980-04-14 1982-08-31 Burroughs Wellcome Co. Compounds and methods of making
US4356165A (en) * 1980-04-14 1982-10-26 Burroughs Wellcome Co. Bupropion radioimmunoassay, and kit
US4435449A (en) * 1981-05-14 1984-03-06 Burroughs Wellcome Co. Treatment of minimal brain dysfunction (MBD)
US4425363A (en) * 1981-05-14 1984-01-10 Burroughs Wellcome Co. Treatment of tardive dyskinesia in mammals
US4393078A (en) * 1982-03-15 1983-07-12 Burroughs Wellcome Co. Bupropion and ethanol
US4438138A (en) * 1982-12-06 1984-03-20 Burroughs Wellcome Co. Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4507323A (en) * 1984-07-25 1985-03-26 Burroughs Wellcome Co. Treatment of psychosexual dysfunctions
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
DE10075031I2 (de) * 1984-08-17 2004-07-01 Wellcome Found Zusammensetzung zur kontrollierten Abgabe eines Wirkstoffs.
AU657973B2 (en) * 1991-05-07 1995-03-30 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation

Also Published As

Publication number Publication date
CA2142320C (fr) 2001-10-09
ES2111168T3 (es) 1998-03-01
WO1994004138A1 (fr) 1994-03-03
MX9304967A (es) 1994-05-31
NZ254947A (en) 1996-04-26
KR100294154B1 (ko) 2001-09-17
CY2143B1 (en) 2002-06-21
DE69316015T2 (de) 1998-04-16
AU677595B2 (en) 1997-05-01
IL106693A (en) 1997-06-10
GR3025794T3 (en) 1998-03-31
JPH08500110A (ja) 1996-01-09
KR950702827A (ko) 1995-08-23
CA2142320A1 (fr) 1994-03-03
US5427798A (en) 1995-06-27
TW260607B (fr) 1995-10-21
ATE161422T1 (de) 1998-01-15
SG43911A1 (en) 1997-11-14
EP0656775B1 (fr) 1997-12-29
ZA935942B (en) 1995-02-13
IL106693A0 (en) 1993-12-08
AU4725893A (en) 1994-03-15
GB9217295D0 (en) 1992-09-30
HK1004323A1 (en) 1998-11-20
DE69316015D1 (de) 1998-02-05
EP0656775A1 (fr) 1995-06-14

Similar Documents

Publication Publication Date Title
LU90656I2 (fr) Hydrochlorure de bupropion
USD407492S (en) Blood pressure measuring device
FR2670139B1 (fr) Valve doseuse utilisable en position inversee.
DE68908718D1 (de) Kissen mit abwechselndem druck.
CA96175S (en) Writing instrument
CA2298597A1 (fr) Dispositif de regulation de l'humidite
DE69208635D1 (de) Gegendruckventil
USD372783S (en) Scissors with hanger clip
DE69108492D1 (de) Gegendruck Regelventil.
USD344437S (en) Wrench for a gas meter
DE58906038D1 (de) Druckventil.
NO891112D0 (no) Artikkel til benyttelse innen protetisk teknikk.
USD408753S (en) Article of jewelry
USD439506S1 (en) Swiveling chain clip
USD350651S (en) Portable one-leg seat
USD391291S (en) Ornamental pen
USD360958S (en) Flashlight
USD318098S (en) Valve check member
DE68917331D1 (de) Hochdruckventil mit flexiblem Sitz.
USD364917S (en) Flood stopper
USD427452S (en) Desk arrangement
USD320988S (en) Telephone keyset
USD275045S (en) Combined bed and control unit for an industrial oxygen concentrator or the like
FR2668238B3 (fr) Reducteur de pression avec valve inclinee.
USD400122S (en) Vase